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Abstract
Purpose Oxaliplatin eVect in the treatment of colorectal
cancer is improved upon combination with thymidylate
synthase (TS) inhibitors. Pemetrexed is polyglutamated by
the folylpolyglutamate synthase (FPGS) and blocks folate
metabolism and DNA synthesis by inhibiting TS, dihydro-
folate reductase (DHFR) and glycinamide ribonucleotide
formyltransferase (GARFT). The present study evaluates
the pharmacological interaction between oxaliplatin and
pemetrexed in colorectal cancer cells.
Methods Human HT29, WiDr, SW620 and LS174T cells
were treated with oxaliplatin and pemetrexed. Drug interac-
tion was studied using the combination index method,
while cell cycle was investigated with Xow cytometry. The
eVects of drugs on Akt phosphorylation and apoptosis were
studied with ELISA and Xuorescence microscopy, respec-
tively. RT-PCR analysis was performed to assess whether
drugs modulated the expression of pemetrexed targets and
of genes involved in DNA repair (ERCC1 and ERCC2).
Finally, platinum–DNA adduct levels were detected by
ultra-sensitive multi-collector inductively coupled plasma
mass spectrometry (ICP-MS).
Results A dose-dependent inhibition of cell growth was
observed after drug exposure, while a synergistic interac-
tion was detected preferentially with sequential combinations.
Oxaliplatin enhanced cellular population in the S-phase. Drug
combinations increased apoptotic indices with respect to
single agents, and both drugs inhibited Akt phosphoryla-
tion. RT-PCR analysis showed a correlation between the
FPGS/(TS £ DHFR £ GARFT) ratio and pemetrexed
sensitivity, as well as a downregulation of ERCC1,
ERCC2, TS, DHFR and GARFT after drug exposure. In
addition, pretreatment with pemetrexed resulted in an
increase of oxaliplatin–DNA adducts.
Conclusion These data demonstrate that oxaliplatin and
pemetrexed synergistically interact against colon cancer
cells, through modulation of cell cycle, inhibition of Akt
phosphorylation, induction of apoptosis and modulation of
gene expression.
Keywords Colon cancer · Oxaliplatin · Pemetrexed · 
Gene expression · DNA repair · DNA adducts
Introduction
Colorectal cancer is the second leading cause of cancer-
related deaths in the western world [1]. During the last
4 decades the thymidylate synthase (TS) inhibitor 5-Xuoro-
uracil (5-FU) has been the treatment of choice for colorec-
tal cancer, in both adjuvant and palliative settings, despite
the fact that as a single agent it produces responses in only
15–20% of metastatic patients [2]. In recent years, the
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combinations of 5-FU or its oral prodrug capecitabine with
irinotecan and oxaliplatin and with novel biological agents
bevacizumab and cetuximab have increased responses in
Wrst-line therapy up to 40% [3].
Oxaliplatin (L-OHP) is a platinum analogue that diVers
from cisplatin by the presence of a diaminocyclohexane
ligand in its chemical structure; it forms mainly intrastrand
links between two adjacent guanine residues, disrupting
DNA replication and transcription [4]. The ability of cells
to repair these platinum-induced DNA lesions or adducts is
known to play an important role in oxaliplatin cytotoxicity.
One of the major DNA repair systems in mammalian cells
is the nucleotide excision repair (NER), which removes
bulky helix distorting adducts produced by oxaliplatin [5].
The excision repair cross-complementing group 1 (ERCC1)
protein is an important factor in the incision process, which
is the rate-limiting step of the pathway. ERCC1 forms a
heterodimer with XPF, and the ERCC1/XPF complex is
responsible for the cleavage of the damaged strand [6]. A
functional ERCC1 is essential to repair the platinum–DNA
adducts and it is involved in drug sensitivity in vitro [7, 8].
Moreover, low ERCC1 gene expression levels correlated
with improved overall survival following 5-FU/oxaliplatin
therapy in advanced colorectal cancer patients [9]. Another
molecular determinant of alkylating agents resistance/sen-
sitivity is the helicase excision repair cross-complementing
group 2 (ERCC2), whose protein levels correlated with
drug cytotoxicity in a panel of cancer cell lines [10].
Fluoropyrimidine resistance in several tumors, including
colorectal cancer may be related to TS expression [11]; in
addition, high levels of dUMP have been found in colorec-
tal tumor samples from patients unresponsive to 5-FU/leu-
covorin [12]. More potent inhibitors of TS and newer
antifolates may overcome these resistance mechanisms and
lead to improved drug eYcacy. Furthermore, these drugs
would be beneWcial to treat patients with dihydropyrimi-
dine dehydrogenase deWciency, which results in severe
adverse reactions to 5-FU [13].
Pemetrexed is a multitarget antifolate (MTA) whose
mechanism of action relies mainly on the inhibition of TS,
with weaker secondary eVects on glycinamide ribonucleo-
tide formyltransferase (GARFT) and dihydrofolate reduc-
tase (DHFR), leading to impairment of DNA synthesis and
repair [14]. Pemetrexed is rapidly polyglutamated by the
enzyme folylpolyglutamate synthase (FPGS) and its
polyglutamate derivatives are retained within the cell; this
accumulation represents a substantial pharmacological
advantage, since it produces a prolonged suppression of tar-
get enzymes [15]. Combinations of pemetrexed with agents
such as gemcitabine and platinum compounds are currently
under investigation and have shown in vitro and in the clin-
ical setting promising results in several chemoresistant
tumors [16, 17], including colorectal cancer [18].
In the present study, we have evaluated the pharmaco-
logical interaction between oxaliplatin and pemetrexed and
established the optimal combination schedule in four
human colorectal cancer cell lines. Additional experiments
have explored the molecular and cellular basis of the phar-
macological eVects observed with respect to cell cycle dis-
tribution, induction of apoptosis, Akt phosphorylation,
modulation of gene expression and the formation of oxa-
liplatin–DNA adducts.
Materials and methods
Drugs and chemicals
Oxaliplatin, 5-Xuorouracil and methotrexate (MTX) were
obtained from Sigma Chemical Co. (St. Louis, MO, USA),
while pemetrexed and GARFT inhibitor LY309887 were
generous gifts from Eli Lilly (Indianapolis, IN, USA).
Drugs were dissolved in sterile distilled water and diluted
in culture medium immediately before use. McCoy’s 5A
medium, Leibovitz L-15 medium, Minimum Essential
Medium Eagle (MEME), fetal bovine serum (FBS), L-glu-
tamine, penicillin and streptomycin were obtained from
Gibco (Gaithersburg, MD). All other chemicals were from
Sigma Chemical Co. (St. Louis, MO, USA).
Cell lines
Human colon cancer cells HT29, SW620, WiDr and
LS174T were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were maintained as
monolayer cultures in McCoy’s 5A (HT29), Leibovitz L-15
(SW620) and MEME (WiDr and LS174T) medium, supple-
mented with 10% fetal bovine serum, L-glutamine (2 mM),
penicillin (50 IU/ml) and streptomycin (50 g/ml). Cells
were cultivated in 75 cm2 tissue culture Xasks (Costar,
Cambridge, MA, USA), at 37°C in 5% CO2 and 95% air,
and harvested with trypsin–EDTA when they were in loga-
rithmic growth.
Drug incubations and cytotoxicity assay
Cytotoxicity was assessed by the CellTiter 96 Non-
Radioactive Cell Proliferation Assay (Promega, Madison,
WI, USA) based on the cellular metabolism of the tetra-
zolium compound MTT. Cells were seeded at
5 £ 104 cells/ml in 12-well plates and allowed to attach
for 24 h. Cells were treated with each drug (24 h), either
alone or in combination, as follows: (1) oxaliplatin
0.001 ng/ml–100 g/ml; (2) pemetrexed 0.001 ng/ml–
100 g/ml; (3) oxaliplatin and pemetrexed, simulta-
neously;( 4) oxaliplatin, followed by pemetrexed; (5)Cancer Chemother Pharmacol (2010) 66:547–558 549
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pemetrexed, followed by oxaliplatin. Concentrations for
drug combination studies were based on IC50 values,
representing concentrations resulting in 50% inhibition
of cell growth, obtained from experiments with single
agents. Cells were also treated with 5-Xuorouracil, meth-
otrexate and LY309887 (0.001 ng/ml–100 g/ml) for
gene expression experiments. For cytotoxicity experi-
ments cell cultures were allowed to grow in drug free
medium for an additional 24 h following drug exposure
and growth inhibition was expressed as the percentage
absorbance, relative to untreated control cultures, mea-
sured at 570 nm with a microplate reader (Multiskan
Spectrum, Vantaa, Finland). IC50 values were calculated
using the sigmoid inhibition model (GraphPad PRISM
version 4.0, Intuitive Software for Science, San Diego,
CA, USA).
Drug interaction between oxaliplatin and pemetrexed
was assessed, at a Wxed concentration ratio (see “Results”),
using the combination index, where CI < 1, CI = 1, and
CI > 1 indicate synergistic, additive and antagonistic
eVects, respectively. Data analysis was performed using the
Calcusyn software (Biosoft, Oxford, UK).
Cell cycle analysis
Cells were plated at a density of 1 £ 105 cells/ml in
100 mm Petri dishes (Costar) and treated with oxaliplatin
and pemetrexed at concentrations corresponding to IC50
levels. Cells were harvested immediately after the end of
drug exposure, washed twice with PBS and DNA was
stained with propidium iodide (25 g/ml), RNase (1 mg/ml)
and Nonidet-P40 (0.1%). Samples were kept on ice for
30 min and cytoXuorimetry was performed using a FAC-
Scan (Becton–Dickinson, San José, CA, USA). Data analy-
sis was carried out with CELLQuest (Becton–Dickinson)
and ModWt software (Verity Software, Topsham, ME,
USA).
Analysis of apoptosis
Apoptosis was evaluated in cells treated as described
above for drug incubations and cytotoxicity assays, with
oxaliplatin, pemetrexed and their combinations at IC50
levels. At the end of the incubation period, cells were
washed twice with PBS and Wxed in 4% buVered parafor-
maldehyde for 15 min. Cells were resuspended and incu-
bated for a further 15 min in a solution containing 8 g/ml
bisbenzimide HCl in PBS. A total of 200 cells spotted on
glass slides from randomly chosen microscopic Welds
were examined and counted by Xuorescence microscopy
(Leica, Berlin, Germany) and the percentage of cells dis-
playing apoptotic degeneration relative to the total num-
ber was calculated as the apoptotic index.
Assay of Akt phosphorylation
The eVect of oxaliplatin and pemetrexed treatment on
cellular content of activated Akt was assayed in cells,
treated as described for cell cycle analysis, with a P-Ser473
speciWc ELISA and normalized to the total Akt content
(BioSource International, Camarillo, CA, USA). P-Ser473
Akt and Akt total concentrations were calculated from
standard curves and values of P-Ser473 Akt were then
normalized for total Akt and protein content, measured
with the Lowry reagent (Sigma), as described previously
[19].
Quantitative PCR analysis in cell lines
Cells were plated at a density of 1 £ 105 cells/ml in
100 mm Petri dishes (Costar) and treated with oxalipla-
tin, pemetrexed, 5-Xuorouracil, methotrexate and
LY309887 at concentrations corresponding to IC50 lev-
els. Cells were harvested immediately after the end of
drug exposure, washed twice with PBS and RNA was
extracted using the QiaAmp RNA Mini Kit (Qiagen,
San Diego, CA, USA). The RNA obtained was dissolved
in 10 mM dithiothreitol containing 200 U/ml RNase
inhibitor in RNase free-water, and the absorbance mea-
sured at 260/280 nm, using the Uvikon-940 spectropho-
tometer (Kontron, Milan, Italy). RNA (1 g) was reverse
transcribed at 37°C for 1 h in a 50 l reaction volume
containing 0.8 mM dNTPs, 200 U of MMLV-RT, 40 U
of RNase inhibitor, and 0.05 g/ml of random primers.
The resulting cDNA was ampliWed by quantitative PCR
with the Applied Biosystems 7900HT sequence detec-
tion system (Applied Biosystems, Foster City, CA,
USA). PCR reactions were performed in triplicate using
5 l of cDNA, 12.5 l of TaqMan Universal PCR Master
Mix, 2.5 l of probe and 2.5 l of forward and reverse
primers in a Wnal volume of 25 l. Samples were ampli-
Wed using the following thermal proWle: 50°C for 2 min,
95°C for 10 min, 40 cycles of denaturation at 95°C for
15 s followed by annealing and extension at 60°C for
1m i n .
Forward and reverse primers and probes for FPGS
(NM_004957), TS (NM_0010711), DHFR (NM_000791)
and GARFT (NM_000819) were designed with the Primer
Express version 2.0 software (Applied Biosystems) on the
basis of the gene sequence obtained by the GeneBank data-
base, while primers and probes for ERCC1 (NM_001983)
and for ERCC2 (NM_000400) were obtained from Applied
Biosystems Assay-on-Demand® products (Hs00157415
and Hs00361161).
AmpliWcations were normalized to glyceraldehyde
3-phosphate dehydrogenase (GAPDH). Preliminary
experiments were carried out with dilutions of cDNA550 Cancer Chemother Pharmacol (2010) 66:547–558
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obtained from Quantitative PCR Human Reference Total
RNA (Stratagene, La Jolla, CA, USA) to demonstrate
that the eYciencies of ampliWcation of the target and ref-
erence genes are approximately equal and to determine
the absolute value of the slope of standard cDNA con-
centration versus CT, where CT is the threshold cycle, as
previously reported [20].
Results of basal expression analysis of single genes (TS,
DHFR, GARFT and FPGS) or combined genes [FPGS/
(TS £ DHFR £ GARFT)] were related to pemetrexed
chemosensitivity, while quantiWcation of gene expression
in treated cells was performed using the CT calculation.
The amount of target gene, normalized to GAPDH and rel-
ative to the calibrator (untreated control cells), was
expressed as 2¡CT and reported as percent variation with
respect to control.
Oxaliplatin–DNA adduct formation in cell lines
Cells were plated at a density of 1 £ 105 cells/ml in
100 mm Petri dishes (Costar) and allowed to attach for
24 h prior to drug treatment. Cells were pretreated with
pemetrexed, based on IC50 values determined for each
cell line, prior to incubation with oxaliplatin as follows:
(1) no drug control (26 h incubation); (2) no drug (24 h),
followed by oxaliplatin 300 M (2 h); (3) pemetrexed
10£ below IC50 (24 h), followed by oxaliplatin 300 M
(2 h); (4) pemetrexed at IC50 (24 h), followed by oxalipl-
atin 300 M (2 h); (5) pemetrexed 10£ above IC50
(24 h), followed by oxaliplatin 300 M (2 h). Cells were
harvested immediately after the end of drug exposure,
washed twice with PBS and DNA extracted using the
Qiagen DNA Mini kit (Qiagen, San Diego, USA). The
concentration of DNA in each sample was quantiWed by
UV absorption (A260). DNA samples were diluted in
3.5% nitric acid and hydrolyzed overnight at 70°C. Plat-
inum–DNA adduct levels were determined by ultra-sen-
sitive multi-collector inductively coupled plasma mass
spectrometry (ICP-MS) as previously described [21, 22].
The limits of detection and quantitation using this meth-
odology were 0.3 and 1 attomoles platinum/ml (1 attomole =
1 £ 10¡18 mole/ml), respectively. Final platinum–DNA
adduct levels were calculated as nmoles/g DNA and the
results of duplicate analyzes were within 10% of each
other in all cases.
Statistical methods
All experiments were performed in triplicate and data were
expressed as mean values §SD and were analysed by Stu-
dent’s t test or ANOVA, followed by the Tukey’s test for
multiple comparisons. Statistical signiWcance was set at
P <0 . 0 5 .
Results
Cytotoxicity
Oxaliplatin was cytotoxic against colon cancer cell lines
with IC50 values of 0.33 § 0.02 (HT29), 0.13 § 0.01
(WiDr), 1.13 § 0.35 (SW620) and 0.19 § 0.01 (LS174T)
g/ml, after 24 h exposure. A dose-dependent inhibition of
cell growth by pemetrexed was also observed in all cell
lines, with IC50 values of 5.10 § 0.42, 1.14 § 0.15,
0.87 § 0.23, and 1.05 § 0.36 g/ml in HT29, WiDr,
SW620, and LS174T cells, respectively (Fig. 1).
Pharmacological interaction between oxaliplatin 
and pemetrexed
Because the CI method recommends a ratio of IC50 values
at which drugs are equipotent, the combination studies were
performed at Wxed concentrations ratios (oxalipla-
tin:pemetrexed) of 1:15 (HT29), 1:9 (WiDr), 1:1 (SW620)
and 1:5 (LS174T). The three combination schedules
(oxaliplatin + pemetrexed, oxaliplatin ! pemetrexed and
pemetrexed ! oxaliplatin) reduced the IC50 values of oxa-
liplatin in all cell lines (Fig. 1). Indeed, the analysis of drug
interaction revealed synergistic eVects (CI < 1) with both
simultaneous and sequential treatments; the sequences
oxaliplatin ! pemetrexed and pemetrexed ! oxaliplatin
proved to be the most eVective in all cell lines studied
(Table 1).
Cell cycle perturbations
Treatment with oxaliplatin signiWcantly increased the per-
centage of HT29, SW620, and LS174T cells in the S-phase
with respect to controls (Table 2); whereas a minimal
enhancement was detected in WiDr cells. The cell cycle
eVects of pemetrexed were also evaluated; DNA content
histograms of all cell lines showed an accumulation of cells
at the G1–S-phase, determining an increase in the percent-
age of cells scored for G1 phase (Table 2).
Induction of apoptosis
The four colon cancer cell lines exposed to oxaliplatin,
pemetrexed and drug combinations presented typical apop-
totic morphology with cell shrinkage, nuclear condensation
and fragmentation, and rupture of cells into debris. The
occurrence of apoptosis was signiWcantly higher in oxalipl-
atin and pemetrexed-treated cells with respect to controls
(apoptotic index 8.8 § 2.1% and 8.4 § 0.7% vs.
4.4 § 1.1% in HT29 cells, respectively). Simultaneous
administration and sequential combinations of oxaliplatin
and pemetrexed further increased the apoptotic index withCancer Chemother Pharmacol (2010) 66:547–558 551
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respect to controls (Fig. 2a). In particular, in HT29 and
WiDr cells, all combinations signiWcantly increased the
apoptotic index as compared to cells treated with oxalipla-
tin and pemetrexed alone (P < 0.05), whereas in SW620
and LS174T cell lines, a signiWcantly higher percentage of
apoptotic cells was detected only after treatment with the
pemetrexed ! oxaliplatin combination sequence.
Inhibition of Akt phosphorylation
Oxaliplatin and pemetrexed were able to signiWcantly
reduce the amount of phosphorylated Akt in all cell lines,
with pemetrexed being more potent than oxaliplatin, partic-
ularly in HT29 and SW620 cells. The amount of phosphor-
ylated Akt was decreased up to 51.9 § 6.5% and
83.4 § 0.5% by oxaliplatin, and up to 78.7 § 3.5% and
94.7 § 1.1% by pemetrexed, in HT29 and SW620 cells,
respectively (Fig. 2b).
Gene expression analysis
Pemetrexed modulated gene expression levels of ERCC1
and ERCC2 are shown in Fig. 3a. In particular, pemetrexed
signiWcantly reduced ERCC1 gene expression in HT29 and
LS174T cell lines. Similar results were observed for
ERCC2, whose expression was signiWcantly decreased by
pemetrexed up to 59.8 § 5.0% in HT29 cells, 36.8 § 3.0%
in WiDr cells and 22.6 § 7.4% in SW620 cells. Additional
experiments were designed to demonstrate which of the tar-
get enzymes of pemetrexed contributed to the modulation
of ERCC1 and ERCC2. For this proposal, mRNA levels of
ERCC1 and ERCC2 were analyzed after exposure to
Fig. 1 Dose-response cytotox-
icity of oxaliplatin (L-OHP), 
pemetrexed (MTA) and their 
combinations in HT29, WiDr, 
SW620 and LS174T colon can-
cer cells. Data represent the 
mean percentage of proliferating 
cells (§SD) from three indepen-
dent experiments. In combina-
tion experiments the values refer 
to oxaliplatin concentration
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selective inhibitors of TS (5-FU), DHFR (MTX) and
GARFT (LY309887). No signiWcant changes in ERCC1/2
levels were detected with 5-FU, MTX or LY309887 in
WiDr, SW620 and LS174T cells, while 5-FU treatment
reduced ERCC1 and ERCC2 expression in HT29 cells by
34.1 § 3.6% and 47.2 § 8.3%, respectively (Fig. 3b).
Basal mRNA levels of FPGS, TS, DHFR and GARFT
were analyzed in all cell lines (Table 3) and related to
pemetrexed sensitivity. None of the target genes, taken
individually, were clearly related to cell sensitivity to
pemetrexed. However, a good correlation was found
between the ratio of FPGS/(TS £ DHFR £ GARFT) and
IC50 values of pemetrexed (R2 = 0.954, P = 0.024). Finally,
oxaliplatin signiWcantly modulated basal gene expression
of pemetrexed target enzymes in WiDr, SW620 and
LS174T cells (Fig. 3c). In particular, TS mRNA expression
was signiWcantly decreased by up to 25.7 § 4.0% and
39.0 § 6.0% in SW620 and LS174T cells, respectively.
DHFR and GARFT mRNA expression was markedly
reduced in LS174T cells (78.5 § 3.5% and 72.2 § 4.4%,
respectively) with smaller decreases observed in WiDr and
SW620 cells.
Oxaliplatin–DNA adduct formation
Following treatment of cells with oxaliplatin (300 M) for
2 h, oxaliplatin–DNA adduct levels of 18.5 § 4.3,
76.5 § 31.6, 90.8 § 47.5, and 103.8 § 39.2 nmol/g DNA
were observed in SW620, WiDr, HT29 and LS174T cells,
respectively (mean § SD,  n = 3). An inverse correlation
was observed between oxaliplatin–DNA adduct formation
and oxaliplatin IC50 values for the cell lines studied
Table 1 Combination index 
values for oxaliplatin and 
pemetrexed at 50, 75 and 90% 
growth inhibition
Cell line Treatment IC50 (ng/ml)a Combination Indexb
50%c 70% 90%
HT29 L-OHP + MTA 46.38 § 7.42 0.28 0.17 0.15
L-OHP ! MTA 3.05 § 0.87 0.02 0.04 0.14
MTA ! L-OHP 9.26 § 1.12 0.06 0.01 <0.01
WiDr L-OHP + MTA 13.30 § 1.54 0.22 0.27 0.36
L-OHP ! MTA 1.80 § 0.24 0.03 0.03 0.03
MTA ! L-OHP 2.70 § 0.56 0.04 0.01 <0.01
SW620 L-OHP + MTA 317.40 § 23.10 0.51 0.29 0.12
L-OHP ! MTA 168.30 § 13.50 0.18 0.14 0.09
MTA ! L-OHP 75.40 § 8.97 0.04 0.03 0.01
LS174T L-OHP + MTA 0.36 § 0.08 0.04 0.05 0.09
L-OHP ! MTA 0.06 § 0.01 <0.01 <0.01 <0.01
MTA ! L-OHP 0.04 § 0.01 <0.01 <0.01 <0.01
a IC50 values calculated with re-
spect to oxaliplatin
b Mean data from three indepen-
dent experiments (SD < 10% in 
all cases)
c Inhibition levels
Table 2 Cell cycle modulation after 24 h drug exposure
a Mean data from three independent experiments (SD < 10% in all cases)
b DiVerences () calculated with respect to controls
* P <0 . 0 5
Cell line Treatment G1a phase (%) G1b S-phase (%) S G2/M phase (%) G2/M
HT 29 Control 69.3 26.2 4.5
L-OHP 48.9 ¡20.4* 40.9 +14.7* 10.2 +5.7*
MTA 75.5 +6.2 24.5 ¡1.7 0 ¡4.5*
WiDr Control 69.7 24.5 5.8
L-OHP 61.9 ¡7.8 27.5 +3.0 10.5 +4.7
MTA 72.2 +2.5 27.8 +3.3 0 ¡5.8*
SW620 Control 49.5 44.9 5.5
L-OHP 37.5 ¡12.0* 57.1 +12.2* 5.4 ¡0.1
MTA 67.2 +17.7* 30.2 ¡14.7* 2.6 ¡2.9
LS174T Control 56.4 33.5 10.1
L-OHP 41.1 ¡15.3* 50.0 +16.5* 8.9 ¡1.2
MTA 65.1 +8.7 34.6 +1.1 0.4 ¡9.7*Cancer Chemother Pharmacol (2010) 66:547–558 553
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(R2 = 0.851), with higher levels of platinum–DNA adduct
formation being associated with decreased IC50 values.
There was a trend towards higher levels of oxaliplatin–
DNA adducts being formed following pretreatment with
pemetrexed, with increased adduct levels observed at
pemetrexed concentrations ¸IC50 concentrations in all four
cell lines studied. SigniWcant increases in adduct formation
were observed at IC50 pemetrexed concentrations in
SW620 and LS174T cells and at 10£ IC50 pemetrexed con-
centrations in SW620 and HT29 cells, as compared to con-
trol cells incubated with oxaliplatin in the absence of
pemetrexed (P < 0.05 in all cases). Figure 4 shows the
extent of oxaliplatin–DNA adduct formation in SW620
cells in the presence of increasing concentrations of
pemetrexed; a similar pattern was observed in the other cell
lines studied.
Discussion
The present study demonstrates that oxaliplatin and
pemetrexed exhibit synergistic interactions in a panel of
colorectal cancer cell lines, supporting the role of oxa-
liplatin combinations with TS inhibitors. Limited
published preclinical research focusing on this issue
has shown synergistic activity following simultaneous
Fig. 2 a Percentage of cells 
with apoptotic morphology eval-
uated following treatment with 
oxaliplatin (L-OHP), pemetr-
exed (MTA) and their combina-
tions. Data represent mean 
values §SD from three indepen-
dent experiments. For single 
drug incubations, *P < 0.05, 
**P < 0.01 versus control; for 
drug combinations *P <0 . 0 5 ,  
**P < 0.01, ***P < 0.001 ver-
sus oxaliplatin and pemetrexed 
alone. b Reduction of P-Ser473 
Akt by oxaliplatin (L-OHP) and 
pemetrexed (MTA) in HT29, 
WiDr, SW620 and LS174T co-
lon cancer cells. Data represent 
mean values §SD from three 
independent experiments. 
*P < 0.05, **P <0 . 0 1 ,  
***P < 0.001 with respect to 
control
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exposure to pemetrexed and oxaliplatin in parental and
5-FU-resistant human HT29 colon cancer cells, with
additive antitumor eVects and minimal toxicity in athy-
mic mice bearing HT29 xenografts [23]. Despite the lim-
ited availability of preclinical data, the association of
pemetrexed (500 mg/m2) and oxaliplatin (120 mg/m2),
every 21 days for 6 cycles, was studied as Wrst-line ther-
apy in a phase II trial, reporting a clinical response rate of
29.6% in patients with metastatic adenocarcinoma of the
colon or rectum [18].
Fig. 3 Gene expression analy-
sis of selected genes involved in 
the activity of oxaliplatin and 
pemetrexed. a modulation of 
ERCC1 and ERCC2 mRNA 
expression by pemetrexed, at 
IC50 levels. b Modulation of 
ERCC1 and ERCC2 mRNA 
expression by 5-Xuorouracil 
(5-FU), methotrexate, 
LY309887, at IC50 levels, in 
HT29 cells. c FPGS, TS, DHFR 
and GARFT mRNA modulation 
after oxaliplatin exposure at IC50 
levels. Data represent mean 
values §SD from three indepen-
dent experiments*P <0 . 0 5 ,  
**P < 0.01, ***P < 0.001 with 
respect to control. In particular, 
the results of the repeated mea-
sures ANOVA followed by the 
Tukey’s test were 0.001, 0.007, 
0.033 and 0.045 for the modula-
tion of ERCC1 and ERCC2 after 
pemetrexed exposure in the 
HT29, WiDR, SW620 and 
LS174T cells, respectively; 
0.023 for the modulation of 
ERCC1 and ERCC2 after 5-FU 
exposure in the HT29 cells; and 
0.023, 0.003 and <0.001 for the 
modulation of FPGS, TS, DHFR 
and GARFT after oxaliplatin 
exposure, in the WiDr, SW620 
and LS1574T cells, respectively
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Table 3 Gene expression of FPGS and pemetrexed targets
a Mean values calculated from standard curves, normalized with respect to expression values of the housekeeping gene GAPDH
b Ratio calculated with the formula FPGS/(TS £ DHFR £ GARFT); SD < 10% in all cases
Cell line FPGSa TS DHFR GARFT Ratiob
HT29 8.41 § 0.34 7.97 § 0.22 16.55 § 0.83 5.28 § 0.19 0.01
WiDr 11.32 § 0.44 6.12 § 0.20 6.93 § 0.27 4.00 § 0.15 0.07
SW620 29.31 § 1.05 6.32 § 0.24 7.07 § 0.30 8.18 § 0.42 0.08
LS174T 3.61 § 0.11 3.98 § 0.16 5.32 § 0.21 1.93 § 0.09 0.09Cancer Chemother Pharmacol (2010) 66:547–558 555
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However, a recent multi-institutional phase II study
showed that pemetrexed in combination with oxaliplatin is
active and well tolerated as a Wrst-line therapy for advanced
gastric cancer, with response rates comparable to those
achieved in studies using diVerent 5-FU-oxaliplatin combi-
nations, without the inconvenience of prolonged 5-FU
schedules [24].,
The in vitro data obtained in our study demonstrate that
sequential administration of oxaliplatin and pemetrexed
(i.e. oxaliplatin ! pemetrexed and pemetrexed ! oxalipl-
atin) results in greater cytotoxic eVects than those observed
following simultaneous combination of these two drugs.
Generally consistent results were obtained in HT29, WiDr,
SW620, and LS174T colon cancer cells, although some cell
line-dependent eVects were observed.
The signiWcant synergy observed between oxaliplatin
and pemetrexed in sequential combination may be attrib-
uted, at least in part, to cell cycle perturbations, induction
of apoptosis and expression modulation of target enzymes.
Indeed, cell cycle analysis demonstrated a shift towards the
S-phase after oxaliplatin exposure, potentially facilitating
pemetrexed activity. These Wndings are in agreement with
previous data showing an S-phase delay after oxaliplatin
treatment, followed by G2/M accumulation, in various cell
lines, including colorectal cancer cells [25–28]. Pemetrexed
has been shown to induce cell cycle alterations that may
depend on a change in nucleotide pools through inhibition
of its target enzymes TS, DHFR, and GARFT in diVerent
tumor cell lines [16,  19,  29]; the cell cycle eVects of
pemetrexed in the studied colon cancer cell lines were in
agreement with previously published data in HT29 cells
[30].
The phosphatidylinositol-3 kinase (PI3K)/Akt pathway
provides a potent antiapoptotic signal in cancer cells which
might result in chemoresistance to several anticancer agents
[31]. A recent study has shown that endogenous phosphory-
lated Akt levels are much higher in the RKO cells (resistant
to oxaliplatin) than in the HCT116 cells (sensitive to oxa-
liplatin) and Sphingosine kinase isoforms and neutral
sphingomyelinase contribute to the regulation of chemo-
sensitivity by controlling ceramide formation and the
downstream Akt pathway in human colon cancer cells [32].
Furthermore the activation of apoptosis by oxaliplatin
mainly relies on Bax relocalization to the mitochondria and
cytochrome c release in the cytoplasm [33]. Since Akt pre-
vents cytochrome c-induced cleavage of pro-caspase-9
[34], the inhibition of PI3K/Akt pathway may be an eVec-
tive molecular target for oxaliplatin-based combinations.
Therefore, in the present work, we investigated the modula-
tion of Akt phosphorylation, demonstrating that pemetr-
exed signiWcantly decreased the amount of the activated
form of Akt in all tested colon cancer cell lines, most nota-
bly observed in HT29 and SW620 cells. Moreover, our
study also showed that oxaliplatin exposure reduced Akt
activation; thus, the reciprocal improvement of oxaliplatin
and pemetrexed therapeutic potential may depend on
suppression of Akt activity and triggering drug-induced
apoptosis, as suggested for pemetrexed–gemcitabine com-
binations in lung cancer cells [20]. Indeed, exposure of all
studied cell lines to oxaliplatin and pemetrexed resulted in a
signiWcant induction of apoptosis with the sequence
pemetrexed ! oxaliplatin resulting in a signiWcantly
higher increase in apoptotic index as compared to single
agents.
Studies on antifolate-resistant cells overexpressing TS
have shown that resistance to pemetrexed is lower than to
other antifolates, possibly because pemetrexed can inhibit
several folate-dependent reactions. Preclinical Wndings
have suggested that mRNA levels of TS, DHFR, and
GARFT are related to IC50 values of pemetrexed in lung
and bladder cancer cell lines [19, 20, 29]. In contrast,
RT-PCR analysis of TS, GARFT, DHFR, and genes
involved in pemetrexed transport, failed to establish a rela-
tion between gene expression level and chemosensitivity in
gastric cancer cell lines [35]. In the present study, gene
expression was not directly related to pemetrexed cytotox-
icity for any of the genes analyzed. However, a low value
of the FPGS/(TS £ DHFR £ GARFT) ratio was associated
with a decreased cell sensitivity, suggesting that the ratio
between activating enzymes and target enzymes was more
discriminating than either target independently, as previ-
ously described for methotrexate in leukemia cells [36].
Several drugs can modulate TS expression, potentially
inXuencing the activity of TS inhibitors. For example, vino-
relbine has been shown to suppress TS expression in PC14
Fig. 4 Formation of oxaliplatin–DNA adducts in SW620 cells. Cells
were treated with oxaliplatin (L-OHP) at a concentration of 300 M for
2 h, either alone or following a 24 h preincubation with pemetrexed
(MTA) at the IC50 concentration, 10£ below IC50 or 10£ above IC50.
Data represent mean values §SD from three independent experiments.
*P<0.05 with respect to control (oxaliplatin alone)
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cells, resulting in a synergistic interaction with 5-FU treat-
ment [37], while several other drugs, such as platinum
derivatives and irinotecan, can also down-regulate TS lev-
els [38, 39]. Yeh and co-workers [40] provided important
data explaining why a combination of oxaliplatin and 5-FU
resulted in better objective responses in 5-FU-resistant
patients than oxaliplatin alone. Indeed, oxaliplatin treat-
ment caused a signiWcant reduction of free TS protein
expression most likely due to TS downregulation at the
transcriptional level. Our Wndings conWrm the modulation
of TS mRNA levels in SW620 and LS174T cells, and also
provide evidence for the suppression of DHFR and GARFT
by oxaliplatin, thus increasing the FPGS/(TS £ DHFR £
GARFT) ratio and potentially favoring pemetrexed activity.
Due to the accelerated rate of DNA replication in neo-
plastic cells, interruption of folate metabolism and deple-
tion in nucleotide pools causes ineVective DNA synthesis
and repair; furthermore, folate deWciency has been shown
to act synergistically with alkylating agents to increase
DNA strand breaks and mutations as a result of impaired
DNA excision repair [41]. This eVect may depend on drug-
induced inhibition of gene expression of key enzymes in
DNA damage repair systems. In particular, our results have
demonstrated a substantial reduction of transcriptional lev-
els of ERCC1 and ERCC2 in HT29 cells, whereas LS174T
showed a signiWcant decrease of ERCC1, and a signiWcant
reduction of ERCC2 was detected in WiDr and SW620 cell
lines. In the HT29 cell line 5-FU exposure induced a simi-
lar eVect to that of pemetrexed on ERCC1 and ERCC2 gene
expression, as previously detected in a cisplatin-resistant
HST-1 human squamous carcinoma cell line and colorectal
cancer cell lines [42, 43]. However, in WiDr, SW620 and
LS174T cells, inhibition of TS by 5-FU was not suYcient
to modulate mRNA levels of these enzymes aVected by
pemetrexed treatment. Thus, it may be hypothesized that
TS inhibition and thymidine depletion are necessary for
downregulation of studied NER genes, but the
simultaneous inhibition of other folate-dependent enzymes
seems to be required in diVerent cells. These gene expres-
sion data may go some way to explaining the synergistic
interaction observed with the oxaliplatin ! pemetrexed
and pemetrexed ! oxaliplatin combinations.
In addition to these Wndings, preliminary experiments
were carried out to determine the potential impact of
pemetrexed on the direct binding of oxaliplatin to DNA in
the form of oxaliplatin–DNA adducts. These studies
showed a clear trend towards higher levels of oxaliplatin–
DNA adducts being formed following pretreatment with
pemetrexed, providing supportive mechanistic data for the
synergistic eVects observed with this sequential drug
administration. An induced stimulation of oxaliplatin–DNA
adduct formation has previously been correlated with a
potentiation of oxaliplatin cytotoxicity by cetuximab in
HCT-8 colorectal cancer cells. This upregulation was asso-
ciated with similarly reduced expression of ERCC1 at both
the mRNA and protein levels [44].
In conclusion, our results indicate that sequential admin-
istrations of oxaliplatin and pemetrexed result in the most
eVective cytotoxic eVects in colon cancer cell lines. These
Wndings may be explained by favorable modulation of sev-
eral molecular determinants involved in chemosensitivity/
chemoresistance to these cytotoxic agents, including signal
transduction pathways, drug targets and DNA repair sys-
tems. These data add to an increasing number of publica-
tions highlighting the potential clinical beneWts of using
oxaliplatin in combination with other anticancer drugs. For
example, promising preclinical data have recently been
published with respect to the combination of oxaliplatin
and Src inhibitors such as dasatinib [45]. Although
the extrapolation of in vitro data to the clinical setting
should be considered with caution, our results may have
implications for rational development of chemotherapeutic
regimens including oxaliplatin and pemetrexed for the
treatment of colorectal cancer.
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